Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic and Wegovy.

Medicare Part D spending for 10 selected diabetes drugs surged from $7.7 billion in 2019 to $35.8 billion in 2023, an audit ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

UnitedHealth Group slid after The Wall Street Journal reported that the Department of Justice was probing the insurance giant's Medicare billing practices. The company, which had already faced a ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Dr. Alexandra Sowa, an obesity medicine specialist and author of the new book “The Ozempic Revolution” shares the pros ... coverage of anti-obesity medications for Americans with Medicare and Medicaid ...

Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor ... and North Carolina adding coverage in ...